Video

Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL

Author(s):

Jonathan Brammer, MD

In Partnership With:

Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).

Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).

Related Videos
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Related Content
Robert Wesolowski, MD, clinical professor, internal medicine, Ohio State University Comprehensive Cancer Center—James
November 4th 2024

BXQ-350 Is Well Tolerated, Shows Clinical Activity in Advanced Solid Tumors

Alice Mims, MD, medical oncologist, associate professor, the Division of Hematology, The Ohio State University Comprehensive Cancer Center—James
February 26th 2024

Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS

Naresh Bumma, MD, an assistant professor in the Division of Hematology at The Ohio State University Comprehensive Cancer Center—James in Columbus
June 25th 2024

Linvoseltamab Displays Durable Efficacy in Relapsed/Refractory Multiple Myeloma

Matthew Lunning, DO, FACP
January 22nd 2024

Lunning and Maddocks Talk Through Frontline MCL Management

Raj Singh, MD, of The Ohio State University Comprehensive Cancer Center––James
April 23rd 2024

Singh Discusses the Shift Toward Stereotactic Radiation Therapy in Lung Cancer

Head and Neck Cancer
March 16th 2024

Quad Shot Radiation Plus Immunotherapy Improves Local Control in Advanced Head and Neck Cancer